🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-527032-14-00
Completed Phase IV

The RHINOME study

2026-527032-14-00 · tracked via the Priya Life Science EU tracker
Sponsor
Region Hovedstaden
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Respiratory Tract Diseases
Decision date
10/08/2026
Enrollment target
72
Sites
Denmark

Condition studied

Severe asthma

Investigational medicinal product(s)

Tezspire 210 mg solution for injection in pre-filled penTezspire 210 mg solution for injection in pre-filled syringe

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

TSLP protein levels in nasal and bronchial epithelial cell culture supernatant measured 24 hours after stimulation with poly(I:C) at the baseline visit, expressed as log2 fold changes compared to unstimulated controls.

Endpoint detail

TSLP expression (mRNA) in cultured nasal and bronchial epithelial cells measured 3 hours after stimulation with poly(I:C) at the baseline visit, expressed as log2 fold changes compared to unstimulated controls., In bronchial mucosal biopsies, the change, in markers of eosinophilic activation and mast cell phenotypes from baseline to visit 4, in major tissue compartments., In bronchial mucosal biopsies, the baseline values of markers of eosinophilic activation and mast cell phenotypes, compared between CRS and non-CRS groups, in major tissue compartments.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-527032-14-00 on CTIS ↗ ← All trials in the EU